الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Prostate cancer is the most common malignancy in the world Sensitivity and specificity of Transrectal US (TRUS) are low in the localization of prostate cancer. Magnetic resonance imaging (MRI) has a significantly higher sensitivity for tumor detection than does TRUS but, like TRUS, has low specificity. A major advance occurred with introduction of the endorectal coil, which provides better signal to noise ratio and increased the resolution.
Diffusion weighted imaging (DWI) is an advanced MR imaging technique that still needs to be clinically validated in addition to the more commonly used anatomic MR imaging sequences, such as T2-weighted imaging. With the increasing availability of 3-T systems, and with the concomitant use of an endorectal coil, the quality of prostate DWI will further improve and this will likely increase its clinical usefulness.
Dynamic contrast-enhanced MRI (DCE-MRI) of the prostate is increasingly recognized as a potential tool for imaging of prostate cancer, helping prostate cancer localization, and improving local staging performance. This technique should always be used in conjunction with T2-weighted imaging.
MR imaging and MR spectroscopic imaging allow combined structural and metabolic evaluation of prostate cancer location, aggressiveness, and stage, and MR imaging provides clinically and therapeutically relevant information on prostatic and periprostatic anatomy.
Differentiation of prostatitis and BPH from prostate cancer is inadequate with current anatomic MR imaging techniques and combination of T2-WI, DWI, and DCE MRI (Multimodality MRI) increase the ability to detect, localize, stage, and grade prostate carcinoma.
It is hoped that the new advances in MR Imaging will contribute to long-term improvements in morbidity from prostate cancer and patients’ quality of life and to a decrease in mortality from prostate cancer.